Briquilimab

Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria.

Mechanism Of Action

Clinical Development

To date, briquilimab has been evaluated in more than 145 healthy volunteers and patients. This humanized antibody is being studied in Jasper-sponsored clinical trials in multiple diseases.

  • Chronic Spontaneous Urticaria (ongoing): Phase 1b/2a BEACON study to evaluate briquilimab as a chronic therapeutic for patients with Chronic Spontaneous Urticaria. (NCT06162728)
  • Chronic Inducible Urticaria (ongoing): Phase 1b/2a SPOTLIGHT study to evaluate briquilimab as a chronic therapeutic for patients with Chronic Inducible Urticaria.
  • SCID Transplant (ongoing): Phase 1/2 dose-escalation and expansion trial is evaluating briquilimab as a sole conditioning agent to achieve donor stem cell engraftment in patients undergoing hematopoietic stem cell transplantation for SCID, which is potentially curable only by this type of treatment. (NCT02963064)

See our expanding pipeline here.

Top